HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue The Journal of Infectious Diseases Année : 2022

HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

Résumé

Abstract We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6\textendash 7.9) and 4.5 (IQR, 3.5\textendash 5.0) log10 copies/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6\textendash 10.4) and 24 weeks in BP (95% CI, 14.1\textendash 33.9).
Fichier non déposé

Dates et versions

hal-03793462 , version 1 (01-10-2022)

Identifiants

Citer

Jade Ghosn, Lambert Assoumou, Caroline Lascoux-Combe, Gilles Peytavin, Karine Amat, et al.. HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection. The Journal of Infectious Diseases, 2022, 225 (1), pp.116--120. ⟨10.1093/infdis/jiab336⟩. ⟨hal-03793462⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More